Monitor the Q3 2026 earnings call in early November for initial commercial launch strategy and revenue guidance for Liora. The in-house manufacturing capability may improve margins over time, but adoption ramp is uncertain.
Price Chart
Executive Summary
TELA Bio announced FDA 510(k) clearance for its Liora Monofilament Scaffold, a fully resorbable surgical mesh for soft tissue reinforcement. This is the first product fully developed in the company's in-house ISO 8 cleanroom, expanding its portfolio in the soft tissue reconstruction market. No financial terms or revenue guidance were disclosed.
Key Facts
- FDA 510(k) clearance received for Liora Monofilament Scaffold on October 5, 2026.
- Liora is a fully resorbable surgical mesh device for soft tissue reinforcement.
- First implant fully developed in TELA Bio's ISO 8 certified cleanroom in Malvern, PA.
- Product expands TELA Bio's footprint in the soft tissue reconstruction market.
- More details expected on the Q3 2026 earnings call in early November.
Financial Impact
No financial terms or market size estimates disclosed in the filing.
Risk Factors
- Commercial adoption may be slow due to surgeon preference for established mesh products.
- Reimbursement coverage and pricing pressure could limit revenue contribution.
- TELA Bio remains pre-profitability; new product launch adds operating costs without guaranteed revenue.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-113506 |
| Document: tm2627013d1_ex99-1.htm | 0001104659-26-113506 |
| Document: 0001104659-26-113506-index-headers.html | 0001104659-26-113506 |
| Document: 0001104659-26-113506-index.html | 0001104659-26-113506 |
| Document: 0001104659-26-113506.txt | 0001104659-26-113506 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | Press Release | $0.9600 | awaiting T+5 | — | $0.9820 (+2.29%) |
Oct 6, 2026 21d ago | 8-K | $1.07 $1.10 | ▲ +2.34% | ▲ +3.32% | $0.9820 (−8.22%) |
Oct 5, 2026 22d ago | 8-K | $1.14 $1.08 | ▼ −5.26% | ▼ −5.69% | $0.9820 (−13.86%) |
Aug 31, 2026 8w ago | 8-K | $0.7380 $0.8301 | ▲ +12.48% | ▲ +12.62% | $0.9820 (+33.06%) |
Aug 10, 2026 11w ago | 8-K | $0.7900 $0.6430 | ▲ +18.61% | ▲ +18.20% | $0.9820 (−24.30%) |
Jun 11, 2026 19w ago | 3 | $0.8600 $0.8010 | ▼ −6.86% | ▼ −7.53% | $0.9820 (+14.19%) |
Jun 11, 2026 19w ago | 3 | $0.8600 $0.8010 | ▼ −6.86% | ▼ −7.53% | $0.9820 (+14.19%) |
Jun 11, 2026 19w ago | 3 | $0.8600 $0.8010 | ▼ −6.86% | ▼ −7.53% | $0.9820 (+14.19%) |
Jun 11, 2026 19w ago | 3 | $0.8600 $0.8010 | ▼ −6.86% | ▼ −7.53% | $0.9820 (+14.19%) |
May 12, 2026 24w ago | 8-K | $0.9600 $0.8600 | ▼ −10.42% | ▼ −9.26% | $0.9820 (+2.29%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers